NCT05137626

Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

A Phase 1, Open-Label Study to Evaluate the Effect of AT-527 on the Pharmacokinetics of Digoxin in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Drug-drug interaction study of Digoxin and AT-527 (R07496998)

Conditions

• Healthy Volunteers Study

Interventions

Type	Name	Description
DRUG	AT-527 + digoxin	* Day 1: A single dose of digoxin will be administered. * Day 15: A single dose of AT-527 and digoxin will be co-administered.
DRUG	AT-527 + digoxin	* Day 1: A single dose of digoxin will be administered. * Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later).

Timeline

• Start date: 2021-11-03
• Primary completion: 2021-12-12
• Completion: 2021-12-12
• First posted: 2021-11-30
• Last updated: 2022-02-28

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study